1. Jemperli (Dostarlimab): First Immunotherapy for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer Product Name: Jemperli Active Ingredients: Dostarlimab Major Class: Checkpoint Inhibitor Minor Class: PD-1 Dose Forms: Solution for infusion (concentrate) Strength: 500 mg/10 mL Containers: Vial Pack Sizes: One Routes of Administration: Intravenous Pregnancy category: D Other Ingredients: Sodium citrate dihydrate, arginine hydrochloride, citric acid monohydrate, sodium chloride, polysorbate 80 and water for injection About Jemperli (Dostarlimab) Jemperli (chemical name: dostarlimab-gxly) is approved by the U.S. Food and Drug Administration (FDA) in order to treat dMMR endometrial cancer where the cancer is advanced or has returned back, and has got worse despite the treatment with platinum-containing chemotherapy. Endometrial cancer is a kind of cancer that occurs in the lining of the womb (the endometrium). When this cancer is advanced, it has progressed outside the womb to neighboring organs (such as the ovaries), or to organs further far in the body. Jemperli is for patients where the cancer is MSI-H or dMMR (these genetic changes can be recognized by a test using a biopsy). At present scenario treatment options for these patients are limited. This medicinal product is typically supplied as 500 mg/10 mL dosage strength. Note: Jemperli (dostarlimab-gxly 500 mg) also used for solid tumors, as determined by an FDA- approved test, that have progressed on or following previous treatment and who have no satisfactory alternative treatment options. Limitations of Use Age: The safety as well as efficacy of Jemperli in patients aged under 18 years have not been established. Fertility/Pregnancy/Breastfeeding: Jemperli treatment can be responsible for causing harm to a fetus and its use is not recommended during pregnancy. Pregnancy needs to be prevented during therapy with Jemperli and for at least 4-months after the final dose of this medicine. The risks associated with this medication during breastfeeding are not specified and cannot be ruled out. Due to the potential for severe side effects in the breastfed child, women should not breastfeed during treatment and for at least 4-months after the final dose of jemperli 500 mg. Complications of stem cell transplant: Life-threatening and severe transplant-related complications can emerge in such patients who receive a stem cell transplant from a donor prior to or after being treated with this medicine. How Does Jemperli (Dostarlimab) Work

2. Jemperli is an immunotherapy. This is a kind of cancer treatment that is designed to stimulates the immune system (the body’s natural defence system) in order to fight the cancer. Some cancerous cells produce proteins that switch off immune cells. Jemperli attaches to a protein named PD-1 on the immune cells, which halts the cancer switching them off, and helps the immune system fight the cancer. Dosage & Administration The recommended dose of jemperli injection is 500 mg every 3 weeks for the initial 4 doses. Subsequent dosing should start 3 weeks after Dose 4 and is 1,000 mg every 6 weeks (Dose 5 onwards). In other words, for the initial 3 months of treatment, this medicine is administered every 3 weeks, for a total of 4 doses. After that, jemperli dosage is administered every six weeks. This medicinal product is administered via a tube into a vein (intravenous infusion or i.v.) over the time- span of 30 minutes. Special Warnings and Precautions for Use Traceability: In order to enhance the traceability of biological medicinal products, the tradename and the batch number of the administered product should be clearly recorded. Immune-related side effects: Immune-related side effects, which may be severe or fatal, can emerge in patients treated with antibodies inhibiting the PD-1/PD-L1 (programmed cell death protein-1 / programmed death-ligand 1) pathway, including Jemperli. Patients needs to be monitored for signs/symptoms of immune-related side effects. Immune-related pneumonitis: Pneumonitis has been observed in patients receiving Jemperli. Patients needs to be monitored for signs and symptoms of pneumonitis. Suspected pneumonitis needs to be confirmed with the help of radiographic imaging and other causes excluded. Patients should be managed with Jemperli 500 injection treatment modifications and corticosteroids. Immune-related colitis: Jemperli can be responsible for causing immune-related colitis. Patients should be assessed for signs/symptoms of colitis and managed with the help of Jemperli treatment modifications, corticosteroids and antidiarrheal agents. Immune-related hepatitis: Jemperli can be responsible for causing immune-related hepatitis. Patients should be assessed for changes in liver function on a periodic basis as indicated, based on clinical assessment and managed with the help of Jemperli treatment modifications and corticosteroids. Immune-related endocrinopathies: Immune-related endocrinopathies, including thyroiditis, hypothyroidism, hyperthyroidism, hypophysitis, type 1 diabetes mellitus and adrenal insufficiency, have been seen in patients receiving inj dostarlimab 500 mg. Immune-related nephritis: Jemperli can be responsible for causing immune-related nephritis. Patients should be evaluated for changes in renal function and managed with Jemperli treatment modifications and corticosteroids. Immune-related rash:

3. Immune-related rash has been noted in patients receiving Jemperli, including pemphigoid. Patients should be assessed for signs/symptoms of rash. Stevens-Johnson Syndrome or toxic epidermal necrolysis events have been seen in patients taken treatment with PD-1 inhibitors. Caution should be imposed when considering the use of Jemperli in a patient who has earlier experienced a life-threatening or severe skin side effects on previous treatment with other immune- stimulatory anticancer medicinal products. Infusion-related reactions: Jemperli can be responsible for causing infusion-related reactions, which may be serious. For serious (grade-3) or life-threatening (grade-4) infusion-related reactions, the infusion should be interrupted and treatment should be permanently discontinued. Jemperli Side Effects Like most cancer treatments, Jemperli injection 500 mg can be responsible for causing side effects, some of them serious. The most commonly reported side effects of Jemperli are: • fatigue • weakness • diarrhea • nausea • low red blood cell counts (anemia) Jemperli also can be responsible for causing other serious side effects, including: Pneumonia: Jemperli treatment may cause inflammation of the lungs, which may be life- threatening. Symptoms include worsening cough, trouble breathing, and chest pain. Colitis (inflammation of the inner lining of the colon): Signs and symptoms include severe stomach pain, diarrhea, and blood or mucus in the stool. Liver problems: Jemperli may be responsible for causing hepatitis (inflammation of the liver). Patients should tell their health specialist right away if they have yellowing of your skin or the whites of their eyes, bleeding or bruising a bit more easily than normal, dark-colored urine, severe nausea or vomiting, or pain on the right side of stomach area. Hormone gland problems: Treatment with dostarlimab 500mg injection may affect glands that make certain hormones our body needs in order to function properly, including the thyroid, pancreas, adrenal glands, and pituitary gland. Signs/symptoms include persistent headaches, weight gain or loss, extreme tiredness, feeling cold, changes in mood/behavior, and constipation. Skin problems: This medicinal product may be responsible for causing life-threatening inflammation of the skin and mucous membranes. Patients should tell their doctor right away in case they develop a painful rash and blisters that peel and weep. Their skin also may be red, itchy, and scaly. Severe infection: Signs/symptoms include fever, flu-like symptoms, cough, pain when urinating, or back pain. Special Precautions for Storage

4. This mecicinal product should be stored in a refrigerator 2 °C to 8 °C. Freezing is not recommended. It should be stored in the original package in order to protect from the light. Price/Cost and Availability Jemperli (Dostarlimab) mainly is a novel precision cancer immunotherapy medicine that helps to restore the body’s defense or immune system in fighting cancer by releasing checkpoints that cancer uses in order to shut down the defense/immune system. In order to know the jemperli 500 injection cost in India, and other places, kindly dial our TOLL-FREE Number: 1800-889-1064. Respective or needy individuals can send their requirement via Email: info@indianpharmanetwork.in. It is better to buy this medicine from such pharmaceutical Wholesaler/Supplier that holds the certification of WHO-GDP and ISO 9005 : 2015. If you are looking to buy jemperli 500 mg online at lowest and affordable prices, then Indian Pharma Network is your one-stop solution. Indian Pharma Network is a leading Supplier, Exporter, Retailer and Wholesaler of Generic & Branded Prescription medicines. Where Can I Get More Deets (Jemperli) In order to get more deets about Jemperli, kindly get in touch with your health specialist or pharmacist. Your health specialist or pharmacist can provide more deets about Jemperli (dostarlimab). Note: This information is provided by Indian Pharma Network is for informational and educational purposes only and should not be relied upon for any medical or diagnostic purpose, or for the treatment of any kind of condition or symptom. The information do not constitute the practice of medical, nursing, or professional health care advice or services, and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Source - https://namepatientprogram.blogspot.com/2022/06/dostarlimab-medicine-for- endometrial.html